Table 1.
Characteristics of the included studies
| Study | Intervention | Control | Country | Recruitment period | Time from first ischemic event to randomization | Stroke subtype at inclusiona | Age (mean) | Sex (% males) | Follow-up |
|---|---|---|---|---|---|---|---|---|---|
| Plehn 1999 [30] | Pravastatin 40 mg/day | Placebo | USA and Canada | Dec 1989–Dec 1991 | NA | Both cardio and non-cardio | NA | NA | 5 years |
| White 2000 [31] | Pravastatin 40 mg/day | Placebo | Australia and New Zealand | June 1990–Dec 1992 | NA | Both cardio and non-cardio | NA | NA | 6 years |
| Collins 2004 [32] | Simvastatin 40 mg/day | Placebo | UK | July 1994–May 1997 | > 6 months | Both cardio and non-cardio | 66 | 75% | 5 years |
| Amarenco 2006 [33] | Atorvastatin 80 mg/day | Placebo | World | Sept 1998–Mar 2001 | 1–6 months | Non-cardio | 63 | 60% | 4 years |
| Kennedy 2007 [34] | Simvastatin 40 mg/day | Placebo | USA and Canada | May 2003–Dec 2006 | ≤ 24 h | Both cardio and non-cardio | 68 | 48% | 90 days |
| Yakusevich 2012 [35] | Simvastatin 40 mg/day | No statin | Russia | 2008–2010 | 24–48 h | Both cardio and non-cardio | 66 | 44% | 1 year |
| Hosomi 2015 [36] | Pravastatin 10 mg/day | No statin | Japan | Mar 2004–Feb 2009 | 1 months–3 years | Non-cardio | 66 | 69% | 5 years |
| Ueno 2015 [37] | Rosuvastatin 5 mg/day | No statin | Japan | Aug 2011–Sept 2013 | ≤ 7 days | Non-cardio | 71 | 96% | 6 months |
| Heo 2016 [38] | Rosuvastatin 20 mg/day | Placebo | Korea | Aug 2010–June 2013 | ≤ 66 h | Non-cardio | 65 | 60% | 5 or 14 days |
| Montaner 2016 [39] | Simvastatin 40 mg/day | Placebo | Spain | Apr 2009–Mar 2014 | ≤ 12 h | Both cardio and non-cardio | 74 | 54% | 90 days |
aCardio cardioembolic ischemic stroke, Non-cardio non-cardioembolic ischemic stroke